The efficacy and safety of antiviral therapy with lamivudine to stop the vertica

StephenW

Eur J Clin Microbiol Infect Dis. 2012 Feb 8. [Epub ahead of print]
The efficacy and safety of antiviral therapy with lamivudine to stop the vertical transmission of hepatitis B virus.Yu M, Jiang Q, Ji Y, Jiang H, Wu K, Ju L, Tang X, Wu M.
SourceDepartment of Obstetrics and Gynecology, Second Affiliated Hospital of Southeast University, Nanjing, 210003, China, [email protected].

AbstractThe purpose of this study was to investigate the efficacy and safety of lamivudine (LAM) in stopping the vertical transmission of hepatitis B virus (HBV). Pregnant women with normal alanine transaminase (ALT) (n = 100) and with abnormal ALT (n = 100) who were positive for hepatitis B e antigen (HBeAg), and with HBV DNA (deoxyribonucleic acid) levels ≥1.0 × 10(7) copies/ml were enrolled in this study. One hundred volunteers (50 with normal ALT, 50 with abnormal ALT) received 100 mg of LAM daily from the 24th to 32nd week of gestation and the untreated 100 volunteers served as controls. All infants received passive-active immunoprophylaxis. Compared to the control group, the study group got a marked reduction in serum levels (P < 0.001) and high negativity (P < 0.001) of HBV DNA before delivery. They also got normalization in ALT levels as much as controls received general medication (P > 0.05). The prenatal transmission rate in the study group was significantly lower than that of the control group (P < 0.05). There were no differences in incidences of congenital malformation between the two groups (P > 0.05). LAM treatment can effectively and safely stop vertical transmission of HBV and normalize the ALT levels of pregnant women.

StephenW

欧元微生物临床杂志感染。2012年二月8。 [出处提前打印]
拉米夫定抗病毒治疗的疗效和安全性，阻止乙肝病毒母婴垂直传播。
御米，江Q，姬，姜Ĥ，吴炬大号，唐小，吴M.
源

处，东南大学，南京，210003中国，[email protected]附属第二医院妇产科。

摘要


本研究的目的是在停止乙型肝炎病毒（HBV）母婴垂直传播探讨拉米夫定（LAM）的疗效和安全。与正常的谷丙转氨酶（ALT），（N = 100）与ALT异常组（n =100）谁是B型肝炎阳性孕妇e抗原（HBeAg），乙肝病毒DNA（脱氧核糖核酸）的含量≥1.0×10（7在这项研究中，入选）拷贝/ ml。几百名志愿者（ALT正常，ALT异常5050）从24日至32周妊娠和未经处理的100志愿者作为对照林每日100毫克。所有的婴儿接受被动主动免疫预防。研究组与对照组相比，分娩前的血清水平明显降低（P<0.001）和高（P <0.01），HBV DNA的消极。他们还得到了ALT水平正常化，尽可能控制一般药物性（P>0.05）。研究组在产前传输速率比对照组（P <0.01）显着较低。有先天性畸形的发生率（P <0.05）两组之间没有差异。林治疗可以有效和安全地阻止乙肝病毒母婴垂直传播和孕妇的ALT水平正常化。